Kite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Recept...
September 20 2016 - 4:05PM
Business Wire
Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage
biopharmaceutical company focused on developing engineered
autologous T-cell therapy (eACT™) products for the treatment of
cancer, today announced that the Company has entered into an
exclusive, worldwide license with the National Institutes of Health
(NIH) for intellectual property related to multiple T-cell receptor
(TCR) based product candidates for the treatment of tumors
expressing mutated KRAS antigens.
Kite expects the first of the licensed KRAS product
candidates to enter clinical study in 2016 as part of the Company’s
Cooperative Research and Development Agreement (CRADA) with
the National Cancer Institute (NCI) under the direction of Steven
A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the
NCI.
KRAS is one of the most commonly mutated genes in all of human
cancer and is involved in a broad range of solid tumors, such as
pancreatic, colorectal, and lung cancer, for which there are
significant unmet medical needs.
“Neoantigens are uniquely present in tumors but absent in
healthy tissue which makes them attractive targets for using our
TCR technology,” stated Arie Belldegrun, M.D., FACS, Kite's
Chairman, President and Chief Executive Officer. “Kite has taken an
important step toward building the first therapeutic franchise of
its kind for cancers driven by KRAS mutations and has further
expanded its efforts in building a TCR portfolio across key classes
of antigens, including cancer testis and viral antigens.”
Pursuant to the terms of the license agreement, NIH will receive
from Kite an upfront payment and certain clinical, regulatory, and
sales milestone payments, as well as royalties on net sales of
products covered by the license.
About Kite Pharma
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company
engaged in the development of novel cancer immunotherapy products,
with a primary focus on engineered autologous cell therapy (eACT™)
designed to restore the immune system's ability to recognize and
eradicate tumors. Kite is based in Santa Monica, CA. For more
information on Kite Pharma, please visit www.kitepharma.com. Sign
up to follow @KitePharma on Twitter at
www.twitter.com/kitepharma.
Kite Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The press release may, in some
cases, use terms such as "predicts," "believes," "potential,"
"proposed," "continue," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should" or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: the ability to advance and the success of
TCR-based product candidates directed against KRAS antigens and the
ability, timing and willingness of the NCI to continue research and
development activities pursuant to the CRADA. Various factors may
cause differences between Kite's expectations and actual results as
discussed in greater detail in Kite's filings with the Securities
and Exchange Commission, including without limitation in its Form
10-Q for the quarter ended June 30, 2016. Any forward-looking
statements that are made in this press release speak only as of the
date of this press release. Kite assumes no obligation to update
the forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160920006760/en/
Kite PharmaChristine CassianoSVP, Corporate
Communications & Investor
Relationsccassiano@kitepharma.comorGreg MannVP, Investor
Relationsgmann@kitepharma.com
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Aug 2024 to Sep 2024
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Sep 2023 to Sep 2024